ID   ACE_RAT                 Reviewed;        1313 AA.
AC   P47820; Q7TMC6; Q8CFN1; Q9EQM9;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1996, sequence version 1.
DT   27-MAR-2024, entry version 181.
DE   RecName: Full=Angiotensin-converting enzyme {ECO:0000303|PubMed:8292044};
DE            Short=ACE {ECO:0000303|PubMed:8292044};
DE            EC=3.4.15.1 {ECO:0000250|UniProtKB:P12821};
DE   AltName: Full=Dipeptidyl carboxypeptidase I;
DE   AltName: Full=Kininase II {ECO:0000250|UniProtKB:P12821};
DE   AltName: CD_antigen=CD143;
DE   Contains:
DE     RecName: Full=Angiotensin-converting enzyme, soluble form {ECO:0000250|UniProtKB:P12821};
DE   Flags: Precursor;
GN   Name=Ace {ECO:0000303|PubMed:8292044}; Synonyms=Dcp1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SOMATIC), AND VARIANT LYS-207.
RC   TISSUE=Lung;
RX   PubMed=8292044; DOI=10.1006/bbrc.1994.1053;
RA   Koike G., Krieger J.E., Jacob H.J., Mukoyama M., Pratt R.E., Dzau V.J.;
RT   "Angiotensin converting enzyme and genetic hypertension: cloning of rat
RT   cDNAs and characterization of the enzyme.";
RL   Biochem. Biophys. Res. Commun. 198:380-386(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SOMATIC).
RC   STRAIN=Fischer 344/N, and Lewis/N; TISSUE=Lung;
RA   Jafarian-Tehrani M., Listwak S., Barrientos R.M., Michaud A., Corvol P.,
RA   Sternberg E.M.;
RT   "Characterization of a missense mutation in the angiotensin I-converting
RT   enzyme cDNA in exudative inflammation resistant F344/N rats.";
RL   Submitted (NOV-1999) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TESTIS-SPECIFIC), AND TISSUE
RP   SPECIFICITY.
RC   STRAIN=Sprague-Dawley; TISSUE=Testis;
RX   PubMed=12963491; DOI=10.1016/s0006-2952(03)00457-x;
RA   Tian X.-L., Paul M.;
RT   "Species-specific splicing and expression of angiotensin converting
RT   enzyme.";
RL   Biochem. Pharmacol. 66:1037-1044(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM SOMATIC).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 12-1313 (ISOFORM SOMATIC), AND VARIANT
RP   LYS-207.
RC   TISSUE=Kidney;
RA   Tsetsarkin K.A., Dymshits G.M., Markel A.L., Redina O.E.;
RT   "Analysis of the angiotensin converting enzyme (Ace) cDNA sequence and mRNA
RT   level of expression in WAG and ISIAH rats.";
RL   Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=20487892; DOI=10.1016/0197-0186(82)90081-x;
RA   Benuck M., Berg M.J., Marks N.;
RT   "Separate metabolic pathways for Leu-enkephalin and Met-enkephalin-Arg(6)-
RT   Phe(7) degradation by rat striatal synaptosomal membranes.";
RL   Neurochem. Int. 4:389-396(1982).
RN   [7]
RP   FUNCTION.
RX   PubMed=12500972; DOI=10.1074/jbc.m212030200;
RA   Rioli V., Gozzo F.C., Heimann A.S., Linardi A., Krieger J.E., Shida C.S.,
RA   Almeida P.C., Hyslop S., Eberlin M.N., Ferro E.S.;
RT   "Novel natural peptide substrates for endopeptidase 24.15, neurolysin, and
RT   angiotensin-converting enzyme.";
RL   J. Biol. Chem. 278:8547-8555(2003).
RN   [8]
RP   INDUCTION.
RX   PubMed=15671045; DOI=10.1093/eurheartj/ehi114;
RA   Burrell L.M., Risvanis J., Kubota E., Dean R.G., MacDonald P.S., Lu S.,
RA   Tikellis C., Grant S.L., Lew R.A., Smith A.I., Cooper M.E., Johnston C.I.;
RT   "Myocardial infarction increases ACE2 expression in rat and humans.";
RL   Eur. Heart J. 26:369-375(2005).
RN   [9]
RP   FUNCTION.
RX   PubMed=18077343; DOI=10.1073/pnas.0706980105;
RA   Heimann A.S., Gomes I., Dale C.S., Pagano R.L., Gupta A., de Souza L.L.,
RA   Luchessi A.D., Castro L.M., Giorgi R., Rioli V., Ferro E.S., Devi L.A.;
RT   "Hemopressin is an inverse agonist of CB1 cannabinoid receptors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:20588-20593(2007).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1306, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
CC   -!- FUNCTION: Dipeptidyl carboxypeptidase that removes dipeptides from the
CC       C-terminus of a variety of circulating hormones, such as angiotensin I,
CC       bradykinin or enkephalins, thereby playing a key role in the regulation
CC       of blood pressure, electrolyte homeostasis or synaptic plasticity (By
CC       similarity). Composed of two similar catalytic domains, each possessing
CC       a functional active site, with different selectivity for substrates (By
CC       similarity). Plays a major role in the angiotensin-renin system that
CC       regulates blood pressure and sodium retention by the kidney by
CC       converting angiotensin I to angiotensin II, resulting in an increase of
CC       the vasoconstrictor activity of angiotensin (By similarity). Also able
CC       to inactivate bradykinin, a potent vasodilator, and therefore enhance
CC       the blood pressure response (By similarity). Acts as a regulator of
CC       synaptic transmission by mediating cleavage of neuropeptide hormones,
CC       such as substance P, neurotensin or enkephalins (By similarity).
CC       Catalyzes degradation of different enkephalin neuropeptides (Met-
CC       enkephalin, Leu-enkephalin, Met-enkephalin-Arg-Phe and possibly Met-
CC       enkephalin-Arg-Gly-Leu) (PubMed:20487892). Acts as a regulator of
CC       synaptic plasticity in the nucleus accumbens of the brain by mediating
CC       cleavage of Met-enkephalin-Arg-Phe, a strong ligand of Mu-type opioid
CC       receptor OPRM1, into Met-enkephalin (By similarity). Met-enkephalin-
CC       Arg-Phe cleavage by ACE decreases activation of OPRM1, leading to long-
CC       term synaptic potentiation of glutamate release (By similarity). Also
CC       acts as a regulator of hematopoietic stem cell differentiation by
CC       mediating degradation of hemoregulatory peptide N-acetyl-SDKP (AcSDKP)
CC       (PubMed:12500972, PubMed:18077343). Acts as a regulator of cannabinoid
CC       signaling pathway by mediating degradation of hemopressin, an
CC       antagonist peptide of the cannabinoid receptor CNR1 (PubMed:12500972,
CC       PubMed:18077343). Involved in amyloid-beta metabolism by catalyzing
CC       degradation of Amyloid-beta protein 40 and Amyloid-beta protein 42
CC       peptides, thereby preventing plaque formation (By similarity).
CC       Catalyzes cleavage of cholecystokinin (maturation of Cholecystokinin-8
CC       and Cholecystokinin-5) and Gonadoliberin-1 (both maturation and
CC       degradation) hormones (By similarity). Degradation of hemoregulatory
CC       peptide N-acetyl-SDKP (AcSDKP) and amyloid-beta proteins is mediated by
CC       the N-terminal catalytic domain, while angiotensin I and
CC       cholecystokinin cleavage is mediated by the C-terminal catalytic region
CC       (By similarity). {ECO:0000250|UniProtKB:P09470,
CC       ECO:0000250|UniProtKB:P12821, ECO:0000269|PubMed:12500972,
CC       ECO:0000269|PubMed:18077343, ECO:0000269|PubMed:20487892}.
CC   -!- FUNCTION: [Angiotensin-converting enzyme, soluble form]: Soluble form
CC       that is released in blood plasma and other body fluids following
CC       proteolytic cleavage in the juxtamembrane stalk region.
CC       {ECO:0000250|UniProtKB:P12821}.
CC   -!- FUNCTION: [Isoform Testis-specific]: Isoform produced by alternative
CC       promoter usage that is specifically expressed in spermatocytes and
CC       adult testis, and which is required for male fertility. In contrast to
CC       somatic isoforms, only contains one catalytic domain. Acts as a
CC       dipeptidyl carboxypeptidase that removes dipeptides from the C-terminus
CC       of substrates (By similarity). The identity of substrates that are
CC       needed for male fertility is unknown. May also have a glycosidase
CC       activity which releases GPI-anchored proteins from the membrane by
CC       cleaving the mannose linkage in the GPI moiety. The GPIase activity was
CC       reported to be essential for the egg-binding ability of the sperm. This
CC       activity is however unclear and has been challenged by other groups,
CC       suggesting that it may be indirect (By similarity).
CC       {ECO:0000250|UniProtKB:P09470, ECO:0000250|UniProtKB:P12821}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Release of a C-terminal dipeptide, oligopeptide-|-Xaa-Yaa,
CC         when Xaa is not Pro, and Yaa is neither Asp nor Glu. Thus, conversion
CC         of angiotensin I to angiotensin II, with increase in vasoconstrictor
CC         activity, but no action on angiotensin II.; EC=3.4.15.1;
CC         Evidence={ECO:0000250|UniProtKB:P12821};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=angiotensin I + H2O = angiotensin II + L-histidyl-L-leucine;
CC         Xref=Rhea:RHEA:63560, ChEBI:CHEBI:15377, ChEBI:CHEBI:58506,
CC         ChEBI:CHEBI:147350, ChEBI:CHEBI:147392; EC=3.4.15.1;
CC         Evidence={ECO:0000250|UniProtKB:P12821};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:63561;
CC         Evidence={ECO:0000250|UniProtKB:P12821};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=bradykinin + H2O = bradykinin(1-7) + L-Phe-L-Arg;
CC         Xref=Rhea:RHEA:71451, ChEBI:CHEBI:15377, ChEBI:CHEBI:132988,
CC         ChEBI:CHEBI:133147, ChEBI:CHEBI:147352;
CC         Evidence={ECO:0000250|UniProtKB:P12821};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:71452;
CC         Evidence={ECO:0000250|UniProtKB:P12821};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + substance P = L-Leu-L-Met-NH2 + substance P(1-9);
CC         Xref=Rhea:RHEA:71459, ChEBI:CHEBI:15377, ChEBI:CHEBI:190692,
CC         ChEBI:CHEBI:190693, ChEBI:CHEBI:190700;
CC         Evidence={ECO:0000250|UniProtKB:P12821};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:71460;
CC         Evidence={ECO:0000250|UniProtKB:P12821};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + substance P = Gly-L-Leu-L-Met-NH2 + substance P(1-8);
CC         Xref=Rhea:RHEA:71463, ChEBI:CHEBI:15377, ChEBI:CHEBI:190692,
CC         ChEBI:CHEBI:190694, ChEBI:CHEBI:190699;
CC         Evidence={ECO:0000250|UniProtKB:P12821};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:71464;
CC         Evidence={ECO:0000250|UniProtKB:P12821};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + substance P = L-Phe-L-Phe-Gly-L-Leu-L-Met-NH2 +
CC         substance P(1-6); Xref=Rhea:RHEA:71471, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:190692, ChEBI:CHEBI:190696, ChEBI:CHEBI:190697;
CC         Evidence={ECO:0000250|UniProtKB:P12821};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:71472;
CC         Evidence={ECO:0000250|UniProtKB:P12821};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + neurotensin = L-isoleucyl-L-leucine + neurotensin(1-11);
CC         Xref=Rhea:RHEA:71475, ChEBI:CHEBI:15377, ChEBI:CHEBI:147362,
CC         ChEBI:CHEBI:190704, ChEBI:CHEBI:190706;
CC         Evidence={ECO:0000250|UniProtKB:P12821};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:71476;
CC         Evidence={ECO:0000250|UniProtKB:P12821};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=goralatide + H2O = L-lysyl-L-proline + N-acetyl-L-seryl-L-
CC         aspartate; Xref=Rhea:RHEA:71455, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:190701, ChEBI:CHEBI:190702, ChEBI:CHEBI:190703;
CC         Evidence={ECO:0000250|UniProtKB:P12821};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:71456;
CC         Evidence={ECO:0000250|UniProtKB:P12821};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + Met-enkephalin = L-phenylalanyl-L-methionine + L-
CC         tyrosylglycylglycine; Xref=Rhea:RHEA:71483, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:189868, ChEBI:CHEBI:190708, ChEBI:CHEBI:190709;
CC         Evidence={ECO:0000250|UniProtKB:P12821};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:71484;
CC         Evidence={ECO:0000250|UniProtKB:P12821};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + Leu-enkephalin = L-phenylalanyl-L-leucine + L-
CC         tyrosylglycylglycine; Xref=Rhea:RHEA:71487, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:190689, ChEBI:CHEBI:190708, ChEBI:CHEBI:190710;
CC         Evidence={ECO:0000250|UniProtKB:P12821};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:71488;
CC         Evidence={ECO:0000250|UniProtKB:P12821};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + Met-enkephalin-Arg-Phe = L-arginyl-L-phenylalanine +
CC         Met-enkephalin; Xref=Rhea:RHEA:70675, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:189868, ChEBI:CHEBI:189869, ChEBI:CHEBI:189870;
CC         Evidence={ECO:0000269|PubMed:20487892};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:70676;
CC         Evidence={ECO:0000269|PubMed:20487892};
CC   -!- CATALYTIC ACTIVITY: [Isoform Testis-specific]:
CC       Reaction=Release of a C-terminal dipeptide, oligopeptide-|-Xaa-Yaa,
CC         when Xaa is not Pro, and Yaa is neither Asp nor Glu. Thus, conversion
CC         of angiotensin I to angiotensin II, with increase in vasoconstrictor
CC         activity, but no action on angiotensin II.; EC=3.4.15.1;
CC         Evidence={ECO:0000250|UniProtKB:P12821};
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000250|UniProtKB:P12821};
CC       Note=Binds 2 Zn(2+) ions per subunit. {ECO:0000250|UniProtKB:P12821};
CC   -!- COFACTOR: [Isoform Testis-specific]:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000250|UniProtKB:P12821};
CC       Note=Isoform Testis-specific only binds 1 Zn(2+) ion per subunit.
CC       {ECO:0000250|UniProtKB:P12821};
CC   -!- COFACTOR:
CC       Name=chloride; Xref=ChEBI:CHEBI:17996;
CC         Evidence={ECO:0000250|UniProtKB:P12821};
CC       Note=Binds 3 chloride ions per subunit. {ECO:0000250|UniProtKB:P12821};
CC   -!- COFACTOR: [Isoform Testis-specific]:
CC       Name=chloride; Xref=ChEBI:CHEBI:17996;
CC         Evidence={ECO:0000250|UniProtKB:P12821};
CC   -!- ACTIVITY REGULATION: The dipeptidyl carboxypeptidase activity is
CC       strongly activated by chloride. The dipeptidyl carboxypeptidase
CC       activity is specifically inhibited by lisinopril, captopril and
CC       enalaprilat. {ECO:0000250|UniProtKB:P12821}.
CC   -!- ACTIVITY REGULATION: [Isoform Testis-specific]: Strongly inhibited by
CC       lisinopril and captopril. {ECO:0000250|UniProtKB:P12821}.
CC   -!- SUBUNIT: Monomer and homodimer; homodimerizes following binding to an
CC       inhibitor (By similarity). Interacts with calmodulin (CALM1, CALM2 or
CC       CALM3); interaction takes place in the cytoplasmic region and regulates
CC       phosphorylation and proteolytic cleavage (By similarity).
CC       {ECO:0000250|UniProtKB:P12821, ECO:0000250|UniProtKB:P12822}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250|UniProtKB:P12821};
CC       Single-pass type I membrane protein {ECO:0000255}. Cytoplasm
CC       {ECO:0000250|UniProtKB:P09470}. Note=Detected in both cell membrane and
CC       cytoplasm in neurons. {ECO:0000250|UniProtKB:P09470}.
CC   -!- SUBCELLULAR LOCATION: [Angiotensin-converting enzyme, soluble form]:
CC       Secreted {ECO:0000250|UniProtKB:P12821}.
CC   -!- SUBCELLULAR LOCATION: [Isoform Testis-specific]: Cell membrane
CC       {ECO:0000250|UniProtKB:P12821}; Single-pass type I membrane protein
CC       {ECO:0000255}. Secreted {ECO:0000250|UniProtKB:P12821}. Note=The
CC       testis-specific isoform can be cleaved before the transmembrane region,
CC       releasing a soluble form. {ECO:0000250|UniProtKB:P12821}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage; Named isoforms=2;
CC       Name=Somatic;
CC         IsoId=P47820-1; Sequence=Displayed;
CC       Name=Testis-specific; Synonyms=ACE-T;
CC         IsoId=P47820-2, Q8CFN1-1;
CC         Sequence=VSP_037642, VSP_037643;
CC   -!- TISSUE SPECIFICITY: Expressed in brain, kidney, lung, skeletal muscle
CC       and heart. {ECO:0000269|PubMed:12963491}.
CC   -!- TISSUE SPECIFICITY: [Isoform Testis-specific]: Testis-specific isoform
CC       is expressed in spermatocytes, adult testis.
CC       {ECO:0000269|PubMed:12963491}.
CC   -!- INDUCTION: Up-regulated after myocardial infarction.
CC       {ECO:0000269|PubMed:15671045}.
CC   -!- PTM: [Angiotensin-converting enzyme, soluble form]: Produced following
CC       proteolytic cleavage by secretase enzymes that cleave the transmembrane
CC       form in the juxtamembrane stalk region upstream of the transmembrane
CC       region. Cleavage can take place at different sites of the juxtamembrane
CC       stalk region. {ECO:0000250|UniProtKB:P12821}.
CC   -!- PTM: Phosphorylated by CK2 on Ser-1306; which allows membrane retention
CC       (By similarity). Phosphorylated on tyrosine residues on its
CC       extracellular part, promoting cleavage by secretase enzymes and
CC       formation of the soluble form (Angiotensin-converting enzyme, soluble
CC       form) (By similarity). {ECO:0000250|UniProtKB:P12821,
CC       ECO:0000250|UniProtKB:P12822}.
CC   -!- SIMILARITY: Belongs to the peptidase M2 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U03708; AAA82110.1; -; mRNA.
DR   EMBL; U03734; AAA82111.1; -; mRNA.
DR   EMBL; AF201331; AAG35596.1; -; mRNA.
DR   EMBL; AF201332; AAG35597.1; -; mRNA.
DR   EMBL; AF539425; AAN17280.1; -; mRNA.
DR   EMBL; BC085760; AAH85760.1; -; mRNA.
DR   EMBL; AF532783; AAP80808.1; -; mRNA.
DR   EMBL; AF532784; AAP80809.1; -; mRNA.
DR   PIR; JC2038; JC2038.
DR   RefSeq; NP_036676.1; NM_012544.1.
DR   AlphaFoldDB; P47820; -.
DR   SMR; P47820; -.
DR   STRING; 10116.ENSRNOP00000010627; -.
DR   BindingDB; P47820; -.
DR   ChEMBL; CHEMBL2625; -.
DR   DrugCentral; P47820; -.
DR   GuidetoPHARMACOLOGY; 1613; -.
DR   MEROPS; M02.001; -.
DR   MEROPS; M02.004; -.
DR   GlyCosmos; P47820; 14 sites, 5 glycans.
DR   GlyGen; P47820; 14 sites, 5 N-linked glycans (1 site).
DR   iPTMnet; P47820; -.
DR   PhosphoSitePlus; P47820; -.
DR   jPOST; P47820; -.
DR   PaxDb; 10116-ENSRNOP00000010627; -.
DR   ABCD; P47820; 1 sequenced antibody.
DR   Ensembl; ENSRNOT00000010627.9; ENSRNOP00000010627.6; ENSRNOG00000062101.2. [P47820-1]
DR   Ensembl; ENSRNOT00055050997; ENSRNOP00055042007; ENSRNOG00055029388. [P47820-1]
DR   Ensembl; ENSRNOT00060023492; ENSRNOP00060018648; ENSRNOG00060013753. [P47820-1]
DR   GeneID; 24310; -.
DR   KEGG; rno:24310; -.
DR   UCSC; RGD:2493; rat. [P47820-1]
DR   AGR; RGD:2493; -.
DR   CTD; 1636; -.
DR   RGD; 2493; Ace.
DR   eggNOG; KOG3690; Eukaryota.
DR   GeneTree; ENSGT00940000162051; -.
DR   InParanoid; P47820; -.
DR   OMA; DYSDFQD; -.
DR   OrthoDB; 2898149at2759; -.
DR   PhylomeDB; P47820; -.
DR   TreeFam; TF312861; -.
DR   BRENDA; 3.4.15.1; 5301.
DR   Reactome; R-RNO-2022377; Metabolism of Angiotensinogen to Angiotensins.
DR   PRO; PR:P47820; -.
DR   Proteomes; UP000002494; Chromosome 10.
DR   GO; GO:0009925; C:basal plasma membrane; IDA:RGD.
DR   GO; GO:0031526; C:brush border membrane; IDA:RGD.
DR   GO; GO:0005737; C:cytoplasm; ISO:RGD.
DR   GO; GO:0005768; C:endosome; ISO:RGD.
DR   GO; GO:0009897; C:external side of plasma membrane; ISO:RGD.
DR   GO; GO:0070062; C:extracellular exosome; ISO:RGD.
DR   GO; GO:0005615; C:extracellular space; IDA:RGD.
DR   GO; GO:0005764; C:lysosome; ISO:RGD.
DR   GO; GO:0005886; C:plasma membrane; ISS:UniProtKB.
DR   GO; GO:0097225; C:sperm midpiece; IDA:RGD.
DR   GO; GO:0031982; C:vesicle; IDA:RGD.
DR   GO; GO:0031711; F:bradykinin receptor binding; ISO:RGD.
DR   GO; GO:0005516; F:calmodulin binding; IEA:UniProtKB-KW.
DR   GO; GO:0004180; F:carboxypeptidase activity; IEA:UniProtKB-KW.
DR   GO; GO:0031404; F:chloride ion binding; ISS:UniProtKB.
DR   GO; GO:0004175; F:endopeptidase activity; ISO:RGD.
DR   GO; GO:0008238; F:exopeptidase activity; ISO:RGD.
DR   GO; GO:1901363; F:heterocyclic compound binding; IDA:RGD.
DR   GO; GO:0070573; F:metallodipeptidase activity; ISS:UniProtKB.
DR   GO; GO:0004222; F:metalloendopeptidase activity; ISS:UniProtKB.
DR   GO; GO:0008237; F:metallopeptidase activity; IMP:RGD.
DR   GO; GO:0051019; F:mitogen-activated protein kinase binding; ISO:RGD.
DR   GO; GO:0031434; F:mitogen-activated protein kinase kinase binding; ISO:RGD.
DR   GO; GO:0008233; F:peptidase activity; IDA:UniProtKB.
DR   GO; GO:0008241; F:peptidyl-dipeptidase activity; IDA:UniProtKB.
DR   GO; GO:0008240; F:tripeptidyl-peptidase activity; ISO:RGD.
DR   GO; GO:0008270; F:zinc ion binding; ISO:RGD.
DR   GO; GO:0050435; P:amyloid-beta metabolic process; ISO:RGD.
DR   GO; GO:0060978; P:angiogenesis involved in coronary vascular morphogenesis; IMP:RGD.
DR   GO; GO:0002003; P:angiotensin maturation; ISS:UniProtKB.
DR   GO; GO:0038166; P:angiotensin-activated signaling pathway; ISO:RGD.
DR   GO; GO:0031100; P:animal organ regeneration; IMP:RGD.
DR   GO; GO:0050482; P:arachidonic acid secretion; ISO:RGD.
DR   GO; GO:0010815; P:bradykinin catabolic process; IDA:RGD.
DR   GO; GO:0071838; P:cell proliferation in bone marrow; ISO:RGD.
DR   GO; GO:1904045; P:cellular response to aldosterone; IEP:RGD.
DR   GO; GO:0071333; P:cellular response to glucose stimulus; IEP:RGD.
DR   GO; GO:0042755; P:eating behavior; IMP:RGD.
DR   GO; GO:0009792; P:embryo development ending in birth or egg hatching; IMP:RGD.
DR   GO; GO:0007565; P:female pregnancy; IEP:RGD.
DR   GO; GO:0060047; P:heart contraction; ISO:RGD.
DR   GO; GO:0042447; P:hormone catabolic process; ISS:UniProtKB.
DR   GO; GO:0042445; P:hormone metabolic process; ISS:UniProtKB.
DR   GO; GO:0001822; P:kidney development; IEP:RGD.
DR   GO; GO:0048286; P:lung alveolus development; IMP:RGD.
DR   GO; GO:0030324; P:lung development; IEP:RGD.
DR   GO; GO:0008584; P:male gonad development; IEP:RGD.
DR   GO; GO:0090281; P:negative regulation of calcium ion import; IMP:RGD.
DR   GO; GO:1903597; P:negative regulation of gap junction assembly; ISO:RGD.
DR   GO; GO:0010629; P:negative regulation of gene expression; ISO:RGD.
DR   GO; GO:0046325; P:negative regulation of glucose import; IMP:RGD.
DR   GO; GO:0002446; P:neutrophil mediated immunity; ISO:RGD.
DR   GO; GO:0043171; P:peptide catabolic process; IDA:RGD.
DR   GO; GO:0006518; P:peptide metabolic process; IMP:RGD.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IMP:RGD.
DR   GO; GO:0045777; P:positive regulation of blood pressure; IMP:RGD.
DR   GO; GO:0050769; P:positive regulation of neurogenesis; IMP:RGD.
DR   GO; GO:2000170; P:positive regulation of peptidyl-cysteine S-nitrosylation; ISO:RGD.
DR   GO; GO:0003084; P:positive regulation of systemic arterial blood pressure; IMP:RGD.
DR   GO; GO:0045907; P:positive regulation of vasoconstriction; IMP:RGD.
DR   GO; GO:0010608; P:post-transcriptional regulation of gene expression; ISO:RGD.
DR   GO; GO:0060177; P:regulation of angiotensin metabolic process; ISO:RGD.
DR   GO; GO:0008217; P:regulation of blood pressure; IDA:BHF-UCL.
DR   GO; GO:0086091; P:regulation of heart rate by cardiac conduction; ISO:RGD.
DR   GO; GO:1902033; P:regulation of hematopoietic stem cell proliferation; ISO:RGD.
DR   GO; GO:0014910; P:regulation of smooth muscle cell migration; IDA:BHF-UCL.
DR   GO; GO:0048167; P:regulation of synaptic plasticity; ISS:UniProtKB.
DR   GO; GO:0003081; P:regulation of systemic arterial blood pressure by renin-angiotensin; ISO:RGD.
DR   GO; GO:0071548; P:response to dexamethasone; IEP:RGD.
DR   GO; GO:0001666; P:response to hypoxia; IEP:RGD.
DR   GO; GO:0034616; P:response to laminar fluid shear stress; IEP:RGD.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IMP:RGD.
DR   GO; GO:0031667; P:response to nutrient levels; IEP:RGD.
DR   GO; GO:0097066; P:response to thyroid hormone; IEP:RGD.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IEP:RGD.
DR   GO; GO:0007283; P:spermatogenesis; ISO:RGD.
DR   GO; GO:0010814; P:substance P catabolic process; ISS:UniProtKB.
DR   GO; GO:0042310; P:vasoconstriction; IMP:RGD.
DR   CDD; cd06461; M2_ACE; 2.
DR   Gene3D; 1.10.1370.30; -; 1.
DR   InterPro; IPR001548; Peptidase_M2.
DR   PANTHER; PTHR10514; ANGIOTENSIN-CONVERTING ENZYME; 1.
DR   PANTHER; PTHR10514:SF25; ANGIOTENSIN-CONVERTING ENZYME; 1.
DR   Pfam; PF01401; Peptidase_M2; 2.
DR   PRINTS; PR00791; PEPDIPTASEA.
DR   SUPFAM; SSF55486; Metalloproteases ('zincins'), catalytic domain; 2.
DR   PROSITE; PS52011; PEPTIDASE_M2; 2.
DR   PROSITE; PS00142; ZINC_PROTEASE; 2.
PE   1: Evidence at protein level;
KW   Alternative promoter usage; Calmodulin-binding; Carboxypeptidase;
KW   Cell membrane; Cytoplasm; Disulfide bond; Glycoprotein; Hydrolase;
KW   Membrane; Metal-binding; Metalloprotease; Phosphoprotein; Protease;
KW   Reference proteome; Repeat; Secreted; Signal; Transmembrane;
KW   Transmembrane helix; Zinc.
FT   SIGNAL          1..35
FT                   /evidence="ECO:0000250|UniProtKB:P12821"
FT   CHAIN           36..1313
FT                   /note="Angiotensin-converting enzyme"
FT                   /id="PRO_0000028557"
FT   CHAIN           36..1238
FT                   /note="Angiotensin-converting enzyme, soluble form"
FT                   /id="PRO_0000028558"
FT   TOPO_DOM        36..1265
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        1266..1282
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        1283..1313
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          46..630
FT                   /note="Peptidase M2 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01355"
FT   DOMAIN          649..1228
FT                   /note="Peptidase M2 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01355"
FT   REGION          1221..1262
FT                   /note="Juxtamembrane stalk"
FT                   /evidence="ECO:0000250|UniProtKB:P12821"
FT   ACT_SITE        397
FT                   /note="Proton acceptor 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01355"
FT   ACT_SITE        526
FT                   /note="Proton donor 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01355"
FT   ACT_SITE        995
FT                   /note="Proton acceptor 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01355"
FT   ACT_SITE        1124
FT                   /note="Proton donor 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01355"
FT   BINDING         237
FT                   /ligand="chloride"
FT                   /ligand_id="ChEBI:CHEBI:17996"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01355"
FT   BINDING         396
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01355"
FT   BINDING         400
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01355"
FT   BINDING         424
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01355"
FT   BINDING         535
FT                   /ligand="chloride"
FT                   /ligand_id="ChEBI:CHEBI:17996"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01355"
FT   BINDING         797
FT                   /ligand="chloride"
FT                   /ligand_id="ChEBI:CHEBI:17996"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01355"
FT   BINDING         835
FT                   /ligand="chloride"
FT                   /ligand_id="ChEBI:CHEBI:17996"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01355"
FT   BINDING         994
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01355"
FT   BINDING         998
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01355"
FT   BINDING         1022
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01355"
FT   BINDING         1096
FT                   /ligand="chloride"
FT                   /ligand_id="ChEBI:CHEBI:17996"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01355"
FT   BINDING         1100
FT                   /ligand="chloride"
FT                   /ligand_id="ChEBI:CHEBI:17996"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01355"
FT   BINDING         1133
FT                   /ligand="chloride"
FT                   /ligand_id="ChEBI:CHEBI:17996"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01355"
FT   MOD_RES         1306
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   CARBOHYD        44
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        60
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        80
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        117
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        152
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        166
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        324
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        515
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        683
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        701
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        720
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        766
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        948
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1197
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        163..171
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01355"
FT   DISULFID        365..383
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01355"
FT   DISULFID        551..563
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01355"
FT   DISULFID        763..769
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01355"
FT   DISULFID        963..981
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01355"
FT   DISULFID        1149..1161
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01355"
FT   VAR_SEQ         1..581
FT                   /note="Missing (in isoform Testis-specific)"
FT                   /evidence="ECO:0000303|PubMed:12963491"
FT                   /id="VSP_037642"
FT   VAR_SEQ         582..646
FT                   /note="GCSRPWQEVLKDLVGSDALDASALMEYFQPVSQWLQEQNQRNGEVLGWPEYQ
FT                   WRPPLPDNYPEGI -> MGQGWATPGLPRFLFLLLCCGHLLPVLSQVAADHVTANQGIT
FT                   NQATTRSQTTHQSTISQTIQTSNGTPGRGQGHEGARSQGPAGGNSNKTTPCGKEGEACL
FT                   FSSSPPT (in isoform Testis-specific)"
FT                   /evidence="ECO:0000303|PubMed:12963491"
FT                   /id="VSP_037643"
FT   VARIANT         207
FT                   /note="R -> K"
FT                   /evidence="ECO:0000269|PubMed:8292044, ECO:0000269|Ref.5"
FT   CONFLICT        341
FT                   /note="L -> F (in Ref. 2; AAG35596)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1313 AA;  150908 MW;  8CB5D0015F129591 CRC64;
     MGAASGQRGR WPLSPPLLML SLLLLLLLPP SPAPALDPGL QPGNFSADEA GAQLFADSYN
     SSAEVVMFQS TAASWAHDTN ITEENARLQE EAALINQEFA EVWGKKAKEL YESIWQNFTD
     QKLRRIIGSV QTLGPANLPL TQRLQYNSLL SNMSRIYSTG KVCFPNKTAT CWSLDPELTN
     ILASSRNYAK VLFAWEGWHD AVGIPLRPLY QDFTALSNEA YRQDGFSDTG AYWRSWYESP
     SFEESLEHLY HQVEPLYLNL HAFVRRALHR RYGDKYINLR GPIPAHLLGD MWAQSWENIY
     DMVVPFPDKP NLDVTSTMVQ KGWNATHMFR VAEEFFTSLG LSPMPPEFWA ESMLEKPADG
     REVVCHASAW DFYNRKDFRI KQCTRVTMDQ LSTVHHEMGH VQYYLQYKDL HVSLRRGANP
     GFHEAIGDVL ALSVSTPAHL HKIGLLDRVA NDIESDINYL LKMALEKIAF LPFGYLVDQW
     RWGVFSGRTP PSRYNYDWWY LRTKYQGICP PVARNETHFD AGAKFHIPSV TPYIRYFVSF
     VLQFQFHQAL CKEAGHQGPL HQCDIYQSTK AGAKLQQVLQ AGCSRPWQEV LKDLVGSDAL
     DASALMEYFQ PVSQWLQEQN QRNGEVLGWP EYQWRPPLPD NYPEGIDLET DEAKANRFVE
     EYDRTAKVLW NEYAEANWHY NTNITIEGSK ILLQKNKEVS NHTLKYGTWA KTFDVSNFQN
     STIKRIIKKV QNVDRAVLPP NELEEYNQIL LDMETTYSVA NVCYTNGTCL SLEPDLTNIM
     ATSRKYEELL WVWKSWRDKV GRAILPFFPK YVDFSNKIAK LNGYSDAGDS WRSSYESDDL
     EQDLEKLYQE LQPLYLNLHA YVRRSLHRHY GSEYINLDGP IPAHLLGNMW AQTWSNIYDL
     VAPFPSAPSI DATEAMIKQG WTPRRIFKEA DNFFTSLGLL PVPPEFWNKS MLEKPTDGRE
     VVCHASAWDF YNGKDFRIKQ CTSVNMEELV IAHHEMGHIQ YFMQYKDLPV TFREGANPGF
     HEAIGDVLAL SVSTPKHLHS LNLLSSEGSG YEHDINFLMK MALDKIAFIP FSYLIDQWRW
     RVFDGSITKE NYNQEWWSLR LKYQGLCPPV PRSQGDFDPG SKFHVPANVP YIRYFISFII
     QFQFHEALCR AAGHTGPLYK CDIYQSKEAG KLLADAMKLG YSKQWPEAMK IITGQPNMSA
     SAIMNYFKPL TEWLVTENRR HGETLGWPEY TWTPNTARAE GSLPESSRVN FLGMYLEPQQ
     ARVGQWVLLF LGVALLVATV GLAHRLYNIH NHHSLRRPHR GPQFGSEVEL RHS
//
